With an emphasis on women’s health and early-stage cancer therapies, ValiRx Plc is a life science firm. It is happy to announce that, pending standard regulatory due diligence, it plans to name Martin Gouldstone as a non-executive director of the company.
With thirty years of experience in corporate finance and business development in contract research organizations, the healthcare, and pharmaceutical industries, Martin is the CEO of Oncimmune Holdings plc at the moment. Martin was previously Owkin, Inc.’s Global Senior Vice President of Business Development, where he oversaw new strategic research alliances and oversaw the commercial teams in the USA and Europe. Martin most recently served as Chief Business Officer of BenevolentAI, Global Senior Vice President and Head of Capital Solutions for Syneos Health, and Sensyne Health.
Martin was Head of Lifesciences in the UK for BDO, M&A Lead for Europe at Quintiles (now IQVIA Inc.), and held business development and licensing lead roles at Confirmant Ltd. and Sareum Holdings PLC. Martin was formerly a Partner at Results Healthcare (now CG Results Healthcare), where he co-led the healthcare practice. Martin has a great lot of expertise negotiating multi-year research agreements and purchasing and selling deals in both Europe and the US.
In addition, Martin now serves on the board of trustees of Orthopaedic Research UK and hVIVO plc, formerly known as Open Orphan plc, as a non-executive director. Martin has a Bachelor of Science degree in Genetics and has taken several postgraduate courses in management.
The ValiRx PLC Chair, Dr. Kevin Cox, stated that Martin’s broad industry experience will be a great asset to the company’s board, offering guidance and support in all facets of operations. We are excited to collaborate with him and are glad he supports our goal for ValiRx.
The CEO of ValiRx PLC, Dr. Suzy Dilly, expressed her happiness to be working with Martin and drew on his extensive background in company development and deal-making. Martin will support both our licencing efforts and the expansion of Inaphaea Biolabs.
Because it is incorporated into UK domestic law by virtue of the European Union Act 2018, the Company believes that the information in this announcement qualifies as inside information as defined under the Market Abuse Regulations (EU) No. 596/2014. This release is the responsibility of the Company’s Directors.
